《大行報告》花旗下調希慎(00014.HK)目標價至24.1元 評級「買入」
花旗發表研究報告指,希慎(00014.HK)上半年業績遜於預期,是由於翻修工程及寫字樓和住宅市場疲弱導致租金收入下降。集團相對較高的債務和永續證券風險亦將增加其利息支出,並使盈利難以在短期內恢復到疫情前的水平。不過,由於管理層仍以穩定的派息政策為目標,該行預計其目前8%的收益率應會為股價提供支持。該行考慮到較低的租金預估,維持其「買入」評級,目標價由29元下調至24.1元。
該行表示,目前集團的銷售額已恢復至2018年疫情爆發前水平的80%以上,預計到今年12月,其租戶銷售額將恢復至疫情前水平的85%至90%。另外,公司上半年基本利潤低於預期,中期息派27仙,與預測一致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.